Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acrylic Acid Ethyl Ester. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | THRB | P10828 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 10/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acrylic Acid Ethyl Ester SCHEMBL867566 | 0.98 | ALDH1A1 (0.47) | ALDH1A1THRBTSHRNPSR1HPGD | |
| Acrylic Acid Ethyl Ester SCHEMBL7201294 | 0.97 | ALDH1A1 (0.48) | ALDH1A1THRBTSHRNPSR1HPGD | |
| Acrylic Acid Ethyl Ester SCHEMBL27884650 | 0.95 | ALDH1A1 (0.50) | ALDH1A1THRBTSHRNPSR1HPGD | |
| Acrylic Acid Ethyl Ester SCHEMBL12100197 | 0.95 | ALDH1A1 (0.50) | ALDH1A1THRBTSHRNPSR1HPGD | |
| Acrylic Acid Ethyl Ester SCHEMBL27625183 | 0.94 | THRB (0.44) | ALDH1A1THRBTSHRNPSR1HPGD | |
| Acrylic Acid Ethyl Ester SCHEMBL2370487 | 0.94 | ALDH1A1 (0.52) | ALDH1A1THRBTSHRNPSR1HPGD | |
| Acrylic Acid Ethyl Ester SCHEMBL5827836 | 0.93 | ALDH1A1 (0.44) | ALDH1A1THRBTSHRNPSR1HPGD | |
| Acrylic Acid Ethyl Ester SCHEMBL28021684 | 0.93 | ALDH1A1 (0.44) | ALDH1A1THRBTSHRNPSR1HPGD | |
| Acrylic Acid Ethyl Ester SCHEMBL28001077 | 0.91 | ALDH1A1 (0.46) | ALDH1A1THRBTSHRNPSR1HPGD | |
| Acrylic Acid Methyl Ester SCHEMBL28755787 | 0.91 | THRB (0.42) | ALDH1A1THRBTSHRNPSR1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117425471-A | Prolonged release compositions comprising tomoxetine | 图莱克斯制药公司 | 2024-01-19 | — | — | CN | claimed |
| CN-115887397-A | Theophylline skeleton type slow-release core material, preparation method thereof and theophylline slow-release tablet | 广州茂丰药业有限公司 | 2023-04-04 | — | — | CN | claimed |
| US-20120058194-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING SUBSTITUTED BENZIMIDAZOLE DERIVATIVES | DR. REDDY'S LABORATORIES, INC. | 2012-03-08 | — | — | US | claimed |
| EP-1487420-A1 | COATED PHARMACEUTICAL SINGLE-UNIT DELAYED-RELEASE FORMS, BASED ON POLYVINYL ACETATE | BASF AKTIENGESELLSCHAFT (DE) | 2004-12-22 | — | — | EP | claimed |
| WO-2003075896-A1 | COATED PHARMACEUTICAL SINGLE-UNIT DELAYED-RELEASE FORMS, BASED ON POLYVINYL ACETATE | BASF AKTIENGESELLSCHAFT (DE) | 2003-09-18 | — | — | WO | claimed |
| US-20030175342-A1 | Coated pharmaceutical single-unit delayed-release forms, based on polyvinyl acetate | BASF SE (DE) | 2003-09-18 | — | — | US | claimed |
| US-4876092-A | SUSTAINED RELEASE; ACRYLIC POLYMERS, POLYOLS, DRUGS AND PLASTICIZER | TEIKOKU SEIYAKU KABUSHIKI KAISHA (JP) | 1989-10-24 | — | — | US | claimed |
| US-20240165035-A1 | COATED SOLID PHARMACEUTICAL PREPARATION | SSP CO., LTD. (JP) | 2024-05-23 | — | — | US | disclosed |
| EP-4308094-A1 | COATED SOLID PHARMACEUTICAL PREPARATION | SSP Co., Ltd. (JP) | 2024-01-24 | — | — | EP | disclosed |
| CN-117425471-A | Prolonged release compositions comprising tomoxetine | 图莱克斯制药公司 | 2024-01-19 | — | — | CN | disclosed |
| CN-112739333-A | Patch | 海伦特医药有限公司 | 2021-04-30 | — | — | CN | disclosed |
| CN-112638367-A | Oral pharmaceutical dosage form capable of achieving target PK profile, design and preparation method thereof | 南京三迭纪医药科技有限公司 | 2021-04-09 | — | — | CN | disclosed |
| CN-111698983-A | Compound oral pharmaceutical dosage form comprising fixed doses of an ADHD non-stimulant and an ADHD stimulant | 南京三迭纪医药科技有限公司 | 2020-09-22 | — | — | CN | disclosed |
| US-7074428-B2 | Quick disintegrating tablet in buccal cavity and manufacturing method thereof | ASTELLAS PHARMA INC. (JP) | 2006-07-11 | — | — | US | disclosed |
| US-20040071773-A1 | Quick disintegrating tablet in buccal cavity and manufacturing method thereof | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-15 | — | — | US | disclosed |
| US-6656492-B2 | Prepared by spray drying a suspension of a bitter tasting drug and/or a drug of inferior fluidity and mixing the drug-containing particles with a saccharide to form a mixture that is molded. | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2003-12-02 | — | — | US | disclosed |
| US-6597947-B1 | Iontophoresis device | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2003-07-22 | — | — | US | disclosed |
| EP-1295595-A1 | TABLET RAPIDLY DISINTEGRATING IN MOUTH AND PROCESS FOR PRODUCING THE SAME | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-03-26 | — | — | EP | disclosed |
| US-20020071865-A1 | Quick disintegrating tablet in buccal cavity and manufacturing method thereof | ASTELLAS PHARMA INC. (JP) | 2002-06-13 | — | — | US | disclosed |
| EP-1177813-A1 | IONTOPHORESIS DEVICE | HISAMITSU PHARMACEUTICAL CO. INC. (JP) | 2002-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058194-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING SUBSTITUTED BENZIMIDAZOLE DERIVATIVES | HRH2, MLNR, PGC | GAA 52/4885ALDH1A1 524/4885THRB 4347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.